Immune checkpoint inhibitor-based combinations: is dose escalation mandatory for phase I trials?
Fiche publication
Date publication
novembre 2019
Journal
Annals of oncology : official journal of the European Society for Medical Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr EBERST Lauriane
Tous les auteurs :
Simmet V, Eberst L, Marabelle A, Cassier PA
Lien Pubmed
Résumé
Numerous phase I trials testing immune checkpoint inhibitors (CPI)-based combinations are currently being conducted to improve response rates observed with single agents. However, methodology varies across studies, especially regarding the use of dose escalation.
Mots clés
combinations, dose escalation, immune checkpoint inhibitor, immunotherapy, phase I, recommended phase II dose
Référence
Ann Oncol. 2019 11 1;30(11):1751-1759